Zusammenfassung
Es wird über eine Studie berichtet, in welcher versucht wird, durch Verwendung des markierten Liganden Jodobenzamid, der eine sehr hohe D2- Rezeptoraffinität besitzt, D2-Rezeptoren im Gehirn verschiedener Zielgruppen darzustellen. Gesunde Kontrollpersonen, schizophrene Patienten ohne und mit Neuroleptikamedikation wurden untersucht. Die Untersuchung mit Hilfe einer Single-Head-SPECT-Kamera war möglich, die Patienten unter Neuroleptika zeigten ein signifikant niederes Rezeptorbindungsverhältnis im Vergleich zur Kontrollgruppe. Es konnte eine schwache Korrelation zwischen Höhe der neuroleptischen Dosis in Chlorpromazin- einheiten und Verringerung des Rezeptorbindungsquotienten gefunden werden.
Summary
D2-receptors — a key for therapy of schizophrenia. The paper reports a iodobenzamide D2-receptor-binding study. The ligand has a high D2- receptor-affinity, counting was done with a single-head-gamma-camera. A control-group, unmedicated and neuroleptically medicated schizophrenics where studied. The single-head-gamma-camera technique was practicable, medicated schizophrenics showed a significantly lower degree of receptor- binding ratios as compared to controls, the reduction statistically a slight dose dependency (dose in CPU). A single case, indicative for development of “receptor supersensitivity” is presented.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Carlsson A, Lindquist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–144
van Kämmen DP (1979) The dopamine hypothesis of Schizophrenie revisited. Psychoneuroendocrinology 4: 37–46
Baldessarini RJ (1988) Drugs and the treatment of psychiatric disorders. In: Goodman LS, Gillman A (eds) The pharmacological basis of therapeutics, 6th edn. Macmillan, New York, pp 391–425
Seeman P (1981) Dopamine receptors. Pharmacol Rev 32: 229–313
Synder SH (1982) Neurotransmitters and CNS diseases — schizophrenia. Lancet 8305: 970–973
Bunney BS (1984) Antipsychotic drug effects on the electrical activity of dopaminergic neurons. Trends Neurosci 7: 212–215
Mackay AVP, Iversen LL, Rossor M, Spokes E, Birde E, Arregui A, Lreese I, Synder SH (1982) Increased braindopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39: 991–997
Karoum F, Karson CN, Bigelov LB, Labwson WB, Wyatt RJ (1987) Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatry 44: 604–607
Farde L, Ehrin E, Eriksson L, Greitz T, Hall H, Hedström C-G, Litton J-E, Sedvall G (1985) Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 82: 3863–3867
Farde L, Halldin C, Stone-Elander S, Sedvall G (1987) PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C- raclopride. Psychopharmacology 92: 278–284
Farde L, Wiesel FA, Nordstr0m A-L, Sedvall G (1989) Dl-and D2- dopamine receptor occupancy in drug treatment with conventional and atypical neuroleptics. Proc, Clozapine scientific update meeting, Montreux, 1988. Psychopharmacology [Suppl]
Wolkin AT, et al (1988) Dopamine blockade and clinical respose, evidence for two biological subgroups of schizophrenia. NY VA Medical Center
Brücke T, Podreka I, Angelberger P, Steiner M, Topitz A, Walter H, Küfferle B, Müller Ch, Deeke L (1990) Dopamine D2 receptor imaging with SPECT-studies in different neuropsychiatric disorders. J Cereb Blood Flow
Brücke T, Tsai YF, McLellan C, Singhanyom W, Kung HF, Cohen RM, Chiveh CC (1988) In vitro binding properties and autoradiogra¬phic imaging of 3-iodobenzamide ([1251]-IBZM): a portential ima¬ging ligand for D2 dopamine receptor in SPECT. Life Sei 42: 2097–2104
Kung HF, Guo YZ, Billings JB, Xu XJ, March RH, Blau M, Ackerhalt RE (1988) Preparation and biodistribution of (123)-IBZM: a potential CNS D2 dopamine receptor imaging agent. J Nucl Med Biol 15: 195–201
Fritsche H, Benzer MK, Hillbrand E, König P (1991) D2-receptor imaging with single head ECT. Department of Nuclearmedicine and Psychiatry I, Landeskrankenhaus Feldkirch. Society of Nuclear Medicine, 38th Annual Meeting, Cincinatti, June 1991
Haase HH (1972) Therapie mit Psychopharmaka und anderen psy- chotropen Medikamenten. Schattauer, Stuttgart New York
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag/Wien
About this paper
Cite this paper
Benzer, M., König, P. (1992). D2-Rezeptoren — ein Schlüssel in der Schizophrenietherapie. In: König, P. (eds) Rückfallprophylaxe schizophrener Erkrankungen. Aktuelle Probleme der Schizophrenie, vol 3. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9218-4_4
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9218-4_4
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82360-6
Online ISBN: 978-3-7091-9218-4
eBook Packages: Springer Book Archive